



Gefitinib

Data Sheet

Catalog Number:	MC11090	Product Type:	Small Molecule
Bio-Activity:	EGFR-Kinase inhibitor	CAS #:	184475-35-2
Research Categories:	Angiogenesis, cell death, cancer	Chemical Name:	N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
Solubility:	Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 4 mg/ml).	Molecular Formula:	C ₂₂ H ₂₄ ClFN ₄ O ₃
Purity:	> 98%	Molecular Weight:	446.91
Format:	Powder	Ship Temp:	Ambient
Storage:	Room Temperature		

Application Notes

Description/Data:

Potent and selective EGFR kinase inhibitor (IC₅₀ = 23-79 nM) [1]. Inhibits EGFR autophosphorylation and inhibits tumor growth *in vivo* [2]. Enhances efficacy of cytotoxic agents [3]. Inhibits growth factor production and angiogenesis [4]. Clinically useful anticancer agent.

References:

- 1) Baselga et al. (2000), ZD1839 ('Iressa') as an anticancer agent; *Drugs*, 60 33
- 2) McKillop et al. (2005), Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor; *Mol. Cancer Ther.*, 4 641
- 3) Sirotnak et al. (2000), Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase; *Clin. Cancer Res.*, 6 4885
- 4) Ciaradiello et al. (2001), Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor; *Clin. Cancer Res.*, 7 1459

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012